Core Insights - The current obstacles for individuals seeking treatment for obesity through GLP-1 drugs include production bottlenecks, high costs, and insurance reimbursement issues, particularly for seniors on Medicare [2][5] - Psychological barriers also exist, as some individuals are resistant to injectable treatments, preferring not to undergo weekly injections [5] Industry Outlook - By 2026, these barriers are expected to diminish, with drug prices decreasing, expanded insurance coverage, and the anticipated introduction of oral formulations [6] - This shift is projected to significantly increase the population using GLP-1 drugs, representing a major benefit for public health and creating new investment opportunities [6]